Publications & Resources

+ Expand all


Autosomal Dominant Polycystic Kidney Disease
Grantham JJ
N Engl J Med. 359; 14 - October 2, 2008

Cellular signaling in PKD: foreword
Torres VE, and Ong ACM
Cellular Signaling  Volume 71, July 2020, 109625

Volume Progression in Polycystic Kidney Disease
Grantham JJ, Torres VE, Chapman AB, Guay-Woodford LM, Bae KT, King BF Jr, Wetzel LH, Baumgarten DA, Kenney PJ, Harris PC, Klahr S, Bennett WM, Hirschman GN, Meyers CM, Zhang X, Zhu F, and Miller JP, for the CRISP Investigators
N Engl J Med. 354; 20 - May 18, 2006

Blood Pressure in Early Autosomal Dominant Polycystic Kidney Disease
Schrier RW, Abebe KZ, Perrone RD, Torres VE, Braun WE, Steinman TI, Winklhofer FT, Brosnahan G, Czarnecki PG, Hogan MC, Miskulin DC, Rahbari-Oskoui FF, Grantham JJ, Harris PC, Flessner MF, Bae KT, Moore CG, and Chapman AB, for the HALT-PKD Trial Investigators
N Engl J Med. 371; 24 - December 11, 2014


Effect of a Vasopressin V2 Receptor Antagonist on Polycystic Kidney Disease Development in a Rat Model
Wang X, Constans MM, Chebib FT, Torres VE, and Pellegrini L
Am J Nephrol. 49(6):487-493 – May 2019

Lixivaptan, a New Generation Diuretic, Counteracts Vasopressin-Induced Aquaporin-2 Trafficking and Function in Renal Collecting Duct Cells
Di Mise A, Venneri M, Ranieri M, Centrone M, Pellegrini L, Tamma G, and Valenti G
Int J Mol Sci. 26;21(1) – December 2019

Lixivaptan – an evidence-based review of its clinical potential in the treatment of hyponatremia
Bowman BT, Rosner MH.
Core Evid. 2013;8:47-56


Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist
Gattone VH 2nd, Wang X, Harris PC, and Torres VE
Nat Med. 9, 1323–1326 (2003).

Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease
Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, and Czerwiec FS, for the TEMPO 3:4 Trial Investigators
N Engl J Med. 367; 25 - December 20, 2012

Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease
Torres VE, Chapman AB, Devuyst O, Gransevoort RT, Perrone RD, Koch G, Ouyang J, McQuade RD, Blais, JD, Czerwiec FS, and Sergeyeva O, for the REPRISE Trial Investigators*
N Engl J Med. 377:1930-1942 - November 16, 2017


Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database
Watkins PB, Lewis JH, Kaplowitz N, Alpers DH, Blais JD, Smotzer DM, Krasa H, Ouyang J, Torres VE, Czerwiec FS, and Zimmer CA
Drug Saf. 38:1103–1113 – July 2015

Role of Liver Transplantation in Tolvaptan-Associated Acute Liver Failure
Endo M, Katayama K, Matsuo H, Horiike S, Nomura S, Hayashi A, Ishikawa E, Harada T, Sugimoto R, Tanemura A, Sugimoto K, Isaji S and Ito M
Kidney Int Reports. 4:11, 1653–1657 – September 2019

Comparison of the Hepatotoxic Potential of Two Treatments for Autosomal-Dominant Polycystic Kidney Disease Using Quantitative Systems Toxicology Modeling
Woodhead JL, Pellegrini L, Shoda LKM, and Howell BA
Pharm Res. 37:24 – January 2020